Octagon Capital Advisors’s Unicycive Therapeutics UNCY Stock Holding History

Octagon Capital Advisors’s Portfolio UNCY Stock Details UNCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.69M	Hold	1,000,000	–	–	0.42%	25
2026 Q1	$6.58M	Hold	1,000,000	–	–	0.73%	23
2025 Q4	$5.77M	Hold	1,000,000	–	–	0.7%	26
2025 Q3	$4.36M	Hold	1,000,000	–	–	0.66%	24
2025 Q2	$4.77M	Hold	1,000,000	–	–	1.05%	24
2025 Q1	$5.75M	Hold	1,000,000	–	–	1.11%	30
2024 Q4	$7.94M	Buy	1,000,000 +144,100	+17%	+$798K	1.31%	24
2024 Q3	$3.49M	Buy	+855,900	New	+$3.44M	0.54%	30

Other funds holding UNCY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return

Octagon Capital Advisors's UNCY Position: Q2 2026 in Review

Octagon Capital Advisors held its Unicycive Therapeutics (UNCY) position steady in Q2 2026 at 1,000,000 shares worth $4.69M. The position accounts for 0.42% of the portfolio, ranked #25.

Octagon Capital Advisors first reported a position in UNCY in Q3 2024 and has held it in 8 quarters since. The position peaked at $7.94M in Q4 2024. 80 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

Octagon Capital Advisors held 1,000,000 shares of Unicycive Therapeutics worth $4.69M as of Q2 2026.
Octagon Capital Advisors left its Unicycive Therapeutics share count unchanged in Q2 2026.
Unicycive Therapeutics made up 0.42% of Octagon Capital Advisors's portfolio in Q2 2026, its #25 holding.
Octagon Capital Advisors first reported a position in Unicycive Therapeutics in Q3 2024 and has held it in 8 quarters since.
Octagon Capital Advisors's Unicycive Therapeutics position peaked at $7.94M in Q4 2024.
80 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Octagon Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.